In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo.

At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (USFDA), Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results and plans to submit the data as part of its ongoing rolling submission to the USFDA for Emergency Use Authorization (EUA) as soon as possible.

Pfizer's net profit rose 8.8% to Rs 142.95 crore on 6.8% increase in net sales to Rs 636.26 crore in Q2 FY22 over Q2 FY21.

Pfizer is a research-based global biopharmaceutical company which is engaged in the discovery, development and manufacture of healthcare products.